Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. OX40 and 4-1BB delineate distinct immune profiles in sarcoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Small extracellular vesicles: multi-faceted tools for leukemia immune evasion in vivo

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  1. Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. YKL-40: A Cancer Target and Biomarker?

    Publikation: Bog/antologi/afhandling/rapportPh.d.-afhandling

Vis graf over relationer

Galectin-3 (Gal3) can be expressed by many cells in the tumor microenvironment (TME), including cancer cells, cancer-associated fibroblasts, tumor-associated macrophages, and regulatory T cells (Tregs). In addition to immunosuppression, Gal3 expression has been connected to malignant cell transformation, tumor progression, and metastasis. In the present study, we found spontaneous T-cell responses against Gal3-derived peptides in PBMCs from both healthy donors and cancer patients. We isolated and expanded these Gal3-specific T cells in vitro and showed that they could directly recognize target cells that expressed Gal3. Finally, therapeutic vaccination with a long Gal3-derived peptide epitope, which induced the expansion of Gal3-specific CD8+ T cells in vivo, showed a significant tumor-growth delay in mice inoculated with EO771.LMB metastatic mammary tumor cells. This was associated with a significantly lower percentage of both Tregs and tumor-infiltrating Gal3+ cells in the non-myeloid CD45+CD11b- compartment and with an alteration of the T-cell memory populations in the spleens of Gal3-vaccinated mice. These results suggest that by activating Gal3-specific T cells by an immune-modulatory vaccination, we can target Gal3-producing cells in the TME, and thereby induce a more immune permissive TME. This indicates that Gal3 could be a novel target for therapeutic cancer vaccines.

Udgave nummer1
Sider (fra-til)2026020
StatusUdgivet - 27 jan. 2022

Bibliografisk note

© 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

ID: 74338149